Annals of Oncology Advance Access originally published online on December 3, 2007
Annals of Oncology 2008 19(4):746-751; doi:10.1093/annonc/mdm554
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
urogenital tumors |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
1 Department of Medical Oncology, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia
2 Department of Medical Oncology, Centre for the Southern Interior, BC Cancer Agency, Kelowna
3 Department of Medical Oncology, Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
4 Department of Medical Oncology, Cancer Care Manitoba, Winnipeg
5 Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto
6 Department of Medical Oncology, Tom Baker Cancer Centre, Calgary
7 Department of Pathology and Molecular Medicine, Queen’s University, Kingston
8 IND Program, National Cancer Institute of Canada–Clinical Trials Group, Kingston, Canada
* Correspondence to: Dr K. N. Chi, Vancouver Centre, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. Tel: +1-604-877-6000; Fax: +1-604-877-0585; E-mail: kchi{at}bccancer.bc.ca
Background: The purpose of this trial was to evaluate the antitumor activity of sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, in patients with castration-resistant prostate cancer.
Patients and methods: This was a multicenter, two-stage, phase II study. Sorafenib 400 mg was administered orally twice daily continuously. Primary end point was prostate-specific antigen (PSA) ‘response’ defined as a 
50% decrease for 4 weeks.
Results: In all, 28 patients were enrolled. Eastern Cooperative Oncology Group performance status was zero or one in 19 and 9 patients. Two patients had no metastases, and 26 had bone and/or lymph node disease. A median of two cycles (range 1–8) was delivered. Adverse events were typical for sorafenib. The PSA response rate was 3.6% [95% confidence interval (CI) 0.1% to 18.3%] with response occurring in one patient (baseline = 10 000 and nadir = 1643 µg/l). No measurable disease responses occurred in eight patients. Time to PSA progression was 2.3 months (95% CI 1.8–6.4). Of 16 patients who discontinued sorafenib and then did not receive any immediate therapy, 10 had postdiscontinuation PSA declines of 7%–52%.
Conclusions: Sorafenib has limited activity using current PSA criteria. The declines in PSA observed on treatment discontinuation indicate an effect on PSA production/secretion. Further study may be warranted but needs to consider the limitations of PSA as an indicator of progression and response.
Key words: phase II clinical trial, prostate cancer, prostate-specific antigen, sorafenib
Received for publication September 14, 2007. Revision received November 2, 2007. Accepted for publication November 5, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. B. Aragon-Ching and W. L. Dahut About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? Ann. Onc., November 10, 2009; (2009) mdp467v1. [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Song, J. S. Lim, H. J. Yun, S. Kim, D. Y. Kang, and H. J. Lee Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment Jpn. J. Clin. Oncol., September 22, 2009; (2009) hyp110v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann. Onc., July 24, 2009; (2009) mdp323v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, and M. R. Smith Phase II study of sunitinib in men with advanced prostate cancer Ann. Onc., May 1, 2009; 20(5): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Illouz, S. Laboureau-Soares, S. Dubois, V. Rohmer, and P. Rodien Tyrosine kinase inhibitors and modifications of thyroid function tests: a review Eur. J. Endocrinol., March 1, 2009; 160(3): 331 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Colloca, F. Checcaglini, and A. Venturino About sorafenib in castration-resistant prostate cancer Ann. Onc., October 1, 2008; 19(10): 1812 - 1813. [Full Text] [PDF]
|
|